Moreover, we uncover a novel regulation of ET-1 by p53 in ccRCC and show that p53-dependent apoptosis is dependent on mTORC1/2 kinase activity in this tumor type, suggesting that potential combination therapies of chemotherapeutics with mTOR inhibitors need to be carefully evaluated for ccRCC. Here, TP53 is linked to nonpapillary renal cell carcinoma.